{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:10:33Z","timestamp":1788480633402,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Hubei Province of China","award":["2024AFB1030"],"award-info":[{"award-number":["2024AFB1030"]}]},{"name":"CIFST - Abbott Foundation of Food Nutrition and Safety","award":["202305"],"award-info":[{"award-number":["202305"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sarcopenic obesity (SO) is a prognostic factor and its impact on response to immunotherapy is still unknown in lung cancer. We aimed to explore the role of SO and body composition in predicting overall survival (OS) in patients with lung cancer receiving immune checkpoint inhibitors (ICIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study involving 119 patients with lung cancer who underwent immunotherapy. The subcutaneous fat area (SFA), visceral fat area (VFA) and skeletal muscle index (SMI) were determined by the cross-sectional computed tomography at the L3 lumbar vertebral level. Sarcopenia and SO were defined by SMI and body mass index. Kaplan\u2013Meier and Cox proportional hazard analyses were used to evaluate the impact of body composition on survival. The propensity score matching (PSM) analysis was used to reduce bias and a nomogram was created to predict the OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The Kaplan\u2013Meier survival showed that patients with sarcopenia and SO had poor survival time in the total and PSM cohort. The Cox analyses revealed that sarcopenia (Hazard ratio (HR): 2.04, 95% Confidence Interval (CI): 1.04-4.01, P\u2005=\u20050.039) and SO (HR: 3.17, 95%CI: 1.49-6.75, P\u2005=\u20050.003) were independent OS predictors. SFA and VFA were not associated with OS. The SMI, age, stage, albumin level and SFA were used to develop a nomogram. Patients with high nomogram scores had worse OS (P\u2005&amp;lt;\u20050.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Sarcopenia and SO are prognostic factors in patients with lung cancer receiving ICIs. A nomogram that integrates body composition is sufficiently accurate for predicting OS in patients with lung cancer receiving immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf114","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T01:09:11Z","timestamp":1751159351000},"source":"Crossref","is-referenced-by-count":7,"title":["The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study"],"prefix":"10.1093","volume":"30","author":[{"given":"Wen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nutrition, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou, Henan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Imaging, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer center, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Han","sequence":"additional","affiliation":[{"name":"Cancer center, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou, Henan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-5762","authenticated-orcid":false,"given":"Xin","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital , Zhengzhou, Henan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025062821090589500_CIT0001","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"2025062821090589500_CIT0002","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025062821090589500_CIT0003","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025062821090589500_CIT0004","doi-asserted-by":"publisher","first-page":"958505","DOI":"10.3389\/fonc.2022.958505","article-title":"State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer","volume":"12","author":"Yao","year":"2022","journal-title":"Front Oncol"},{"key":"2025062821090589500_CIT0005","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025062821090589500_CIT0006","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025062821090589500_CIT0007","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, pd-l1-expressing, locally advanced or metastatic non-small-cell lung cancer (keynote-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2025062821090589500_CIT0008","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025062821090589500_CIT0009","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/jca.65012","article-title":"Biomarkers for predicting the efficacy of immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer."},{"key":"2025062821090589500_CIT0010","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3892\/ol.2021.12816","article-title":"Challenges in bioinformatics approaches to tumor mutation burden analysis","volume":"22","author":"Fenizia","year":"2021","journal-title":"Oncol Lett"},{"key":"2025062821090589500_CIT0011","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"2025062821090589500_CIT0012","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","article-title":"Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review","volume":"37","author":"Pamoukdjian","year":"2018","journal-title":"Clin Nutr"},{"key":"2025062821090589500_CIT0013","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12672-022-00576-0","article-title":"Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review","volume":"13","author":"Lin","year":"2022","journal-title":"Discov Oncol"},{"key":"2025062821090589500_CIT0014","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10120-017-0722-9","article-title":"Sarcopenia in gastric cancer: when the loss costs too much","volume":"20","author":"Ongaro","year":"2017","journal-title":"Gastric Cancer"},{"key":"2025062821090589500_CIT0015","doi-asserted-by":"publisher","first-page":"816883","DOI":"10.3389\/fnut.2022.816883","article-title":"Prognostic value of sarcopenia in patients with diffuse large b-cell lymphoma treated with r-chop: a systematic review and meta-analysis","volume":"9","author":"Xu","year":"2022","journal-title":"Front Nutr"},{"key":"2025062821090589500_CIT0016","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcsm.13126","article-title":"The prognostic value of sarcopenia in oesophageal cancer: a systematic review and meta-analysis","volume":"14","author":"Fang","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025062821090589500_CIT0017","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcsm.12391","article-title":"Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study","volume":"10","author":"da Rocha","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025062821090589500_CIT0018","doi-asserted-by":"publisher","first-page":"e1580128","DOI":"10.1080\/2162402X.2019.1580128","article-title":"Sub-cutaneous fat mass measured on multislice computed tomography of pretreatment pet\/ct is a prognostic factor of stage iv non-small cell lung cancer treated by nivolumab","volume":"8","author":"Popinat","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025062821090589500_CIT0019","doi-asserted-by":"publisher","first-page":"7429319","DOI":"10.1155\/2022\/7429319","article-title":"Preoperative body composition combined with tumor metabolism analysis by pet\/ct is associated with disease-free survival in patients with nsclc","volume":"2022","author":"Tan","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"2025062821090589500_CIT0020","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and diagnostic criteria for sarcopenic obesity: espen and easo consensus statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes Facts"},{"key":"2025062821090589500_CIT0021","doi-asserted-by":"publisher","first-page":"155639","DOI":"10.1016\/j.metabol.2023.155639","article-title":"Sarcopenic obesity: emerging mechanisms and therapeutic potential","volume":"146","author":"Axelrod","year":"2023","journal-title":"Metabolism"},{"key":"2025062821090589500_CIT0022","doi-asserted-by":"publisher","first-page":"900823","DOI":"10.3389\/fnut.2022.900823","article-title":"Sarcopenia was a poor prognostic predictor for patients with advanced lung cancer treated with immune checkpoint inhibitors","volume":"9","author":"Li","year":"2022","journal-title":"Front Nutr"},{"key":"2025062821090589500_CIT0023","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/01635581.2022.2153879","article-title":"Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis","volume":"75","author":"Ren","year":"2023","journal-title":"Nutr Cancer"},{"key":"2025062821090589500_CIT0024","doi-asserted-by":"publisher","first-page":"e007315","DOI":"10.1136\/jitc-2023-007315","article-title":"Synergic prognostic value of 3d ct scan subcutaneous fat and muscle masses for immunotherapy-treated cancer","volume":"11","author":"Decazes","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"2025062821090589500_CIT0025","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3390\/cancers15051382","article-title":"Association of computed tomography measures of muscle and adipose tissue and progressive changes throughout treatment with clinical endpoints in patients with advanced lung cancer treated with immune checkpoint inhibitors","volume":"15","author":"Khan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025062821090589500_CIT0026","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.2147\/CMAR.S257849","article-title":"Value of visceral fat area in the preoperative discrimination of peritoneal metastasis from gastric cancer in patients with different body mass index: a prospective study","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2025062821090589500_CIT0027","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ajcn\/nqaa305","article-title":"Development and validation of nomograms for the prediction of low muscle mass and radiodensity in gastric cancer patients","volume":"113","author":"Zhang","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"2025062821090589500_CIT0028","article-title":"An automatic screening method for sarcopenia based on artificial intelligence","author":"Xian Shen","year":"2022.11.22"},{"key":"2025062821090589500_CIT0029","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.21037\/atm-21-6578","article-title":"Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-pd-1 immunotherapy","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025062821090589500_CIT0030","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with pd-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"2025062821090589500_CIT0031","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J Oncol"},{"key":"2025062821090589500_CIT0032","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"2025062821090589500_CIT0033","doi-asserted-by":"publisher","first-page":"111704","DOI":"10.1016\/j.nut.2022.111704","article-title":"Prevalence and prognostic value of sarcopenic obesity in patients with cancer: a systematic review and meta-analysis","volume":"101","author":"Gao","year":"2022","journal-title":"Nutrition"},{"key":"2025062821090589500_CIT0034","doi-asserted-by":"publisher","first-page":"101035","DOI":"10.1016\/j.currproblcancer.2023.101035","article-title":"Effects of nutritional indices and inflammatory parameters on patients received immunotherapy for non-small cell lung cancer","volume":"48","author":"Ding","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"2025062821090589500_CIT0035","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chest.2019.04.115","article-title":"Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis","volume":"156","author":"Yang","year":"2019","journal-title":"Chest"},{"key":"2025062821090589500_CIT0036","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.bone.2018.01.004","article-title":"Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers","volume":"108","author":"Chambard","year":"2018","journal-title":"Bone"},{"key":"2025062821090589500_CIT0037","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jgo.2018.05.003","article-title":"Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage i non-small cell lung cancer","volume":"9","author":"Matsuo","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"2025062821090589500_CIT0038","doi-asserted-by":"publisher","first-page":"1261202","DOI":"10.3389\/fimmu.2023.1261202","article-title":"Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy","volume":"14","author":"Kuang","year":"2023","journal-title":"Front Immunol"},{"key":"2025062821090589500_CIT0039","doi-asserted-by":"publisher","first-page":"854096","DOI":"10.3389\/fonc.2022.854096","article-title":"Sarcopenia and systemic inflammation response index predict response to systemic therapy for hepatocellular carcinoma and are associated with immune cells","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"2025062821090589500_CIT0040","doi-asserted-by":"publisher","first-page":"17562848221142417","DOI":"10.1177\/17562848221142417","article-title":"Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with pd-1 inhibitor","volume":"15","author":"Guo","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2025062821090589500_CIT0041","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s41467-019-13204-3","article-title":"Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders pd-1 immunotherapy","volume":"10","author":"Shi","year":"2019","journal-title":"Nat Commun"},{"key":"2025062821090589500_CIT0042","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5493\/wjem.v3.i3.26","article-title":"Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications","volume":"3","author":"Dalamaga","year":"2013","journal-title":"World J Exp Med"},{"key":"2025062821090589500_CIT0043","doi-asserted-by":"publisher","first-page":"e12750","DOI":"10.1111\/acel.12750","article-title":"Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood","volume":"17","author":"Duggal","year":"2018","journal-title":"Aging Cell"},{"key":"2025062821090589500_CIT0044","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.arr.2016.03.006","article-title":"Regenerative function of immune system: modulation of muscle stem cells","volume":"27","author":"Saini","year":"2016","journal-title":"Ageing Res Rev"},{"key":"2025062821090589500_CIT0045","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/01635581.2023.2203355","article-title":"Predictive impact of prognostic nutritional index in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"75","author":"Xu","year":"2023","journal-title":"Nutr Cancer"},{"key":"2025062821090589500_CIT0046","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with pd-1\/pd-l1 inhibitors: results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2025062821090589500_CIT0047","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jcsm.12371","article-title":"Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy","volume":"10","author":"Dijksterhuis","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025062821090589500_CIT0048","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clnu.2015.05.011","article-title":"Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients","volume":"35","author":"Anandavadivelan","year":"2016","journal-title":"Clin Nutr"},{"key":"2025062821090589500_CIT0049","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1007\/s00330-022-09345-7","article-title":"Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study","volume":"33","author":"Wang","year":"2023","journal-title":"Eur Radiol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf114\/63551639\/oyaf114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf114\/63551639\/oyaf114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T01:09:12Z","timestamp":1751159352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf114\/8171907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf114","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf114"}}